Research
Hormonal
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for the treatment of type 2 diabetes and obesity.
Practitioners should consider GLP-1 receptor agonists for managing type 2 diabetes and obesity.
StrongSupportsmedium confidence
Glucagon-like peptide-1 (GLP-1) receptor agonists are widely prescribed for the treatment of type 2 diabetes and obesity.
Why this rating
The claim is based on established therapeutic practices.
Source
Therapeutic strategies, consequences and prospects of glucagon-like peptide-1 agonists
N.M. Bobok · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · 2025
reviewCited 2×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →